Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald W Shipps

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Bioorganic & Medicinal Chemistry Letters|March 29, 2013
Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitorsXiaohua Huang, Cliff C Cheng, Thierry O Fischmann, et al.
Biochemistry|August 20, 2010
Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domainPayal R Sheth, Gerald W Shipps, Wolfgang Seghezzi, et al.
Journal of Lipid Research|February 8, 2011
Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesityHong Lan, Cliff C Cheng, Timothy J Kowalski, et al.
Journal of Medicinal Chemistry|October 15, 2014
Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinaseYongqi Deng, Gerald W Shipps, Alan Cooper, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2013
Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitorYongqi Deng, Gerald W Shipps, Lianyun Zhao, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 InhibitorsStéphane L Bogen, Weidong Pan, Craig R Gibeau, et al.
JCI Insight|February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumorsStergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2010
Structure and activity relationships of tartrate-based TACE inhibitorsDansu Li, Janeta Popovici-Muller, David B Belanger, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2009
The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitorsKristin E Rosner, Zhuyan Guo, Peter Orth, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for OncologySobhana Babu Boga, Yongqi Deng, Liang Zhu, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Bioorganic & Medicinal Chemistry Letters|March 29, 2013
Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitorsXiaohua Huang, Cliff C Cheng, Thierry O Fischmann, et al.
Biochemistry|August 20, 2010
Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domainPayal R Sheth, Gerald W Shipps, Wolfgang Seghezzi, et al.
Journal of Lipid Research|February 8, 2011
Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesityHong Lan, Cliff C Cheng, Timothy J Kowalski, et al.
Journal of Medicinal Chemistry|October 15, 2014
Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinaseYongqi Deng, Gerald W Shipps, Alan Cooper, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2013
Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitorYongqi Deng, Gerald W Shipps, Lianyun Zhao, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 InhibitorsStéphane L Bogen, Weidong Pan, Craig R Gibeau, et al.
JCI Insight|February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumorsStergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2010
Structure and activity relationships of tartrate-based TACE inhibitorsDansu Li, Janeta Popovici-Muller, David B Belanger, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2009
The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitorsKristin E Rosner, Zhuyan Guo, Peter Orth, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for OncologySobhana Babu Boga, Yongqi Deng, Liang Zhu, et al.
Pageof 3